Duration of action and effect on baroreflex function of the anti-arrhythmic alpha 1 antagonist UK-52,046
- PMID: 1676070
- DOI: 10.1111/j.2042-7158.1991.tb05457.x
Duration of action and effect on baroreflex function of the anti-arrhythmic alpha 1 antagonist UK-52,046
Abstract
The effects of acute and chronic oral administration of UK-52,046 (25 micrograms kg-1) on baroreflex function and its duration of action, were studied in conscious dogs. It was found that UK-52,046 had no effect on blood pressure and heart rate following acute and chronic administration. UK-52,046 shifted the phenylephrine dose response curve to the right, and the PE50 (measure of alpha 1-adrenoceptor antagonism) was increased (P less than 0.05) compared to placebo on day 1 (2, 4, 8 and 24 h) and day 8 (2, 4, 8 and 12 h). The antagonism was increased (P less than 0.05) on day 8 (0, 8 and 12 h) compared with day 1. Evaluation of the effects of UK-52,046 on baroreflex function using phenylephrine to increase blood pressure indicated no significant difference from placebo. It was concluded that at an antiarrhythmic dose, UK-52,046 has no effect on blood pressure, heart rate or baroreflex function. The pressor response curve was shifted to the right indicating a duration of action of at least 12 h on chronic oral administration.
Similar articles
-
Dose-dependent alpha 1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man.Br J Clin Pharmacol. 1992 Apr;33(4):405-9. doi: 10.1111/j.1365-2125.1992.tb04059.x. Br J Clin Pharmacol. 1992. PMID: 1349492 Free PMC article. Clinical Trial.
-
Effect of UK-52,046, an alpha 1-adrenoceptor antagonist, on baroreflex function in man.Br J Clin Pharmacol. 1990 Oct;30(4):579-84. doi: 10.1111/j.1365-2125.1990.tb03816.x. Br J Clin Pharmacol. 1990. PMID: 1981319 Free PMC article. Clinical Trial.
-
Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects.Br J Clin Pharmacol. 1991 Nov;32(5):599-604. doi: 10.1111/j.1365-2125.1991.tb03958.x. Br J Clin Pharmacol. 1991. PMID: 1683249 Free PMC article. Clinical Trial.
-
Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: II. Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects.Br J Clin Pharmacol. 1991 Nov;32(5):605-10. doi: 10.1111/j.1365-2125.1991.tb03959.x. Br J Clin Pharmacol. 1991. PMID: 1683250 Free PMC article. Clinical Trial.
-
UK-52,046 (a novel alpha 1-adrenoceptor antagonist) and the role of alpha-adrenoceptor stimulation and blockade on atrioventricular conduction.J Cardiovasc Pharmacol. 1990 Nov;16(5):824-30. doi: 10.1097/00005344-199011000-00020. J Cardiovasc Pharmacol. 1990. PMID: 1703607
Cited by
-
Dose-dependent alpha 1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man.Br J Clin Pharmacol. 1992 Apr;33(4):405-9. doi: 10.1111/j.1365-2125.1992.tb04059.x. Br J Clin Pharmacol. 1992. PMID: 1349492 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources